Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter

Climacteric

Volumn 9, Issue 2, 2006, Pages 146-151

  Tan, D ^a   Darmasetiawan, S ^b   Haines, C J ^b   Huang, K E ^b   Jaisamram, U ^b   Limpaphayom, K K ^b   Lin, S Q ^b   Ling, Y S ^b   Nguyen, T N P ^b   Park, K H ^b   Shah, D ^b   Subramaniam, R ^b   Taechakraichana, N ^b   Xing, S M ^b  

^a United Doctors' Medical Center   (Philippines)

^b NONE

Author keywords

Asian women; Hormone replacement therapy; Menopause; Therapy guidelines

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; GESTAGEN; PROGESTERONE;

ASIA; FEMALE; GENERAL PRACTITIONER; HEALTH PRACTITIONER; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

ASIA; ESTROGEN REPLACEMENT THERAPY; FEMALE; GYNECOLOGY; HUMANS; MENOPAUSE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS;

EID: 33646473077     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130600655852     Document Type: Review

References (28)

1. Naftolin F, Schneider HPG, Sturdee DW for the Executive Committee of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric 2004;7:333-7
2. Gambacciani M, Genazzani AR. The missing R. Gynecol Endocrinol 2003;17:91-4
3. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210
4. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
6. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
7. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-12
8. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57
9. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9
10. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA 1998;279:688-95
11. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. Women's Health Initiative Memory Study. JAMA 2004;291:2947-58
12. Pines A. Compliance with hormone therapy after Women's Health Initiative: who is to blame? Menopause 2005;12:363-5
13. Mikkola TS, Clarkson TB, Notelovitz M. Postmenopausal hormone therapy before and after the Women's Health Initiative study: what consequences? Ann Med 2004;36:402-13
14. Garbe E, Suissa S. Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies. Hum Reprod 2004;19:8-13
15. Skouby SO, Al-Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005;51:8-14
16. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause 2004;11:589-600
17. Posición Latinoamericana en relación con el estado actual de la terapia hormonal. Ginecol Obstet Mex 2005;73:205-11
18. Hilditch JR, Chen S, Norton PG, Lewis J. Experience of menopausal symptoms by Chinese and Canadian women. Climacteric 1999;2:164-73
19. Obermeyer CM. Menopause across cultures: a review of the evidence. Menopause 2000;7:184-92
20. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463-73
21. Avis NE, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52:345-56
22. Fu S-Y, Anderson D, Courtney M. Cross-cultural menopausal experience: comparison of Australian and Taiwanese women. Nurs Health Sci 2003:5:77-84
23. Tan D, Haines CJ, Limpaphayom KK, Holinka CF, Ausmanas MK. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia Menopause (PAM) Study. Maturitas 2005;52:35-51
24. Haines CJ, Xing S-M, Park K-H, Holinka CF, Ausmanas MK. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to three doses of conjugated estrogens/medroxyprogesterone acetate: The Pan-Asia Menopause (PAM) study. Maturitas 2005;52:264-76
25. Salkind NJ. Exploring Research, 4th edn. Upper Saddle River, NJ: Prentice Hall, 2000:132-3
26. Zhao G, Wang L, Yan R, Dennerstein L. Menopausal symptoms: experience of Chinese women. Climacteric 2000;3:135-44
27. Punyahotra S, Dennerstein L, Lehert P. Menopausal experiences of Thai women. 1: Symptoms and their correlates. Maturitas 1997;26:1-7
28. Limpaphayom KK, Taechakraichana N, Jaisamrarn U, et al. Prevalence of osteopenia and osteoporosis in Thai women. Menopause 2001;8:64-9